文献速递泌尿男性生殖肿瘤

评估安全性:晚期前列腺癌中雄激素受体抑制剂的需伤害人数分析

Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer.
PubMed 文献 · Eur J Cancer · 2026-08-08

本研究对非转移性去势抵抗性前列腺癌(nmCRPC)和转移性激素敏感性前列腺癌(mHSPC)中雄激素受体抑制剂(ARI)的不良事件进行需伤害人数(NNH)分析,数据来源于关键试验。结果显示,在nmCRPC中,达罗他胺在潮热、疲劳、关节痛、认知障碍、高血压和跌倒等不良事件上的NNH高于阿帕他胺和恩扎卢胺,风险较低;在mHSPC中趋势相似。需谨慎解读跨试验比较。

要点

  • 达罗他胺在nmCRPC中多数不良事件的NNH高于阿帕他胺和恩扎卢胺,风险较低。
  • mHSPC中达罗他胺同样显示多数不良事件风险较低,但便秘和贫血例外。
  • 跨试验NNH比较需谨慎,因试验设计和人群存在异质性。

核心结论

  • 在nmCRPC和mHSPC患者中,达罗他胺相比阿帕他胺和恩扎卢胺,多数不良事件的增量伤害风险较低。

研究设计与样本

  • 探索性分析,基于关键试验中ARI联合ADT对比ADT的不良事件数据计算NNH。

主要发现

  • nmCRPC中,达罗他胺的NNH(风险较低)高于阿帕他胺和恩扎卢胺:潮热(100.0/未报告[NR]/20.0)、疲劳(29.4/10.8/5.3)、关节痛(负值[NEG]/11.9/100.0)、认知障碍(≥250/47.6/33.3)、高血压(71.4/20.0/14.3)、跌倒(NEG/15.2/14.3)。
  • mHSPC中,达罗他胺在多数所有级别和≥3级不良事件中NNH更高,例外包括所有级别便秘(阿帕他胺和恩扎卢胺NNH更高)和贫血(阿帕他胺NNH更高)。

临床怎么用

  • 了解ARI的风险特征有助于优化治疗选择,改善患者耐受性。

局限性

  • 跨试验NNH比较应谨慎解读,因试验设计和研究人群存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Androgen receptor inhibitors (ARIs) are standard of care in prostate cancer. Patient-centered treatment goals include optimizing efficacy, safety, tolerability, and quality of life, and prolonging time to treatment change. Number needed to harm (NNH) analyses can help contextualize adverse event (AE) risk and support treatment decisions. This exploratory study assessed NNH for AEs of interest with ARIs in nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). METHODS: NNH was calculated using AE data from pivotal trials comparing ARIs plus androgen deprivation therapy (ADT) versus ADT and derived using the reciprocal of the absolute risk increase, then compared between ARIs. RESULTS: In nmCRPC, darolutamide had a higher NNH (lower risk) than apalutamide and enzalutamide for the all-grade AEs hot flash (100.0/not reported [NR])/20.0), fatigue (29.4/10.8/5.3), arthralgia (negative [NEG]/11.9/100.0), cognitive impairment (≥ 250/47.6/33.3), hypertension (71.4/20.0/14.3), and falls (NEG/15.2/14.3) in the primary analysis, a trend generally maintained in the final analysis. A similar trend was reported for most grade ≥ 3 AEs. In mHSPC, darolutamide also had a higher NNH for most all-grade/grade ≥ 3 AEs. Exceptions included all-grade constipation (higher NNH for apalutamide and enzalutamide) and anemia (higher NNH for apalutamide). NNH comparisons across trials should be interpreted cautiously because of heterogeneity in trial designs and study populations. DISCUSSION: Similar NNH trends observed in nmCRPC and mHSPC patient populations suggest a lower risk of incremental harm for most AEs with darolutamide versus apalutamide and enzalutamide. Understanding ARI risk profiles is key to optimizing treatment selection and improving tolerability in patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. George DJ, Fizazi K, Morgans AK, et al. Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer. Eur J Cancer. 2026. PMID: 42617299. doi:10.1016/j.ejca.2026.116982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。